

## HR 6482

### Protecting Our Pharmaceutical Supply Chain from China Act of 2020

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 10, 2020

**Current Status:** Referred to the Subcommittee on Oversight and Investigations.

**Latest Action:** Referred to the Subcommittee on Oversight and Investigations. (Jul 13, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/6482>

## Sponsor

**Name:** Rep. Gallagher, Mike [R-WI-8]

**Party:** Republican • **State:** WI • **Chamber:** House

## Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Budd, Ted [R-NC-13]	R · NC		Apr 10, 2020
Rep. Cheney, Liz [R-WY-At Large]	R · WY		Apr 10, 2020
Rep. Stefanik, Elise M. [R-NY-21]	R · NY		Apr 10, 2020
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Apr 28, 2020
Rep. Hartzler, Vicky [R-MO-4]	R · MO		May 8, 2020
Rep. Posey, Bill [R-FL-8]	R · FL		May 8, 2020
Resident Commissioner González-Colón, Jenniffer [R-PR-At Large]	R · PR		May 15, 2020
Rep. Biggs, Andy [R-AZ-5]	R · AZ		May 22, 2020
Rep. Lesko, Debbie [R-AZ-8]	R · AZ		Jun 8, 2020
Rep. Baird, James R. [R-IN-4]	R · IN		Jul 1, 2020
Rep. Turner, Michael R. [R-OH-10]	R · OH		Oct 27, 2020

## Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Apr 10, 2020
Energy and Commerce Committee	House	Referred To	Apr 10, 2020
Veterans' Affairs Committee	House	Referred to	Jul 13, 2020
Ways and Means Committee	House	Referred to	Apr 10, 2020

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
116 S 3635	Related bill	May 6, 2020: Read twice and referred to the Committee on Finance.
116 S 3537	Identical bill	Mar 19, 2020: Read twice and referred to the Committee on Finance.

## Summary (as of Apr 10, 2020)

### Protecting Our Pharmaceutical Supply Chain from China Act of 2020

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

## Actions Timeline

- **Jul 13, 2020:** Referred to the Subcommittee on Oversight and Investigations.
- **Apr 10, 2020:** Introduced in House
- **Apr 10, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Apr 10, 2020:** Referred to the Subcommittee on Health.